The EPS miss and accelerating cash burn are negative signals for a pre-revenue biotech with no near-term catalyst until summer 2026 enrollment completion. Monitor cash runway closely, the $14.2M cash (plus $10M offering) likely funds operations only into late 2026, requiring additional financing before Phase 3 data readout in early 2027. The 85% enrollment milestone is positive but insufficient to offset the financial deterioration.
ANVS drugs
ANVS drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 15 $2.06entry
- T+1 · 6mo ago −0.49%α −0.42% · $2.05
- T+5 · 6mo ago +8.25%α +7.29% · $2.23
- T+20 · 5mo ago −13.59%α −15.71% · $1.78
- T+60 · 3mo ago −8.25%α −12.77% · $1.89
Price Chart
How similar events traded
Executive Summary
Annovis Bio reported Q1 2026 EPS of -$0.63, significantly below the -$0.35 consensus estimate, with R&D expenses tripling to $16.7M as the Phase 3 AD trial enrollment reached 85%. Cash burn accelerated to $17.6M net loss for the quarter, leaving $14.2M cash on hand (plus $10M from an April offering), funding operations into late 2026 but raising dilution risk ahead of pivotal data readouts in early 2027.
Key Financial Metrics
Key Facts
- Q1 2026 EPS -$0.63 vs consensus -$0.35 (80% miss); net loss widened to $17.6M from $5.5M YoY
- Cash and equivalents $14.2M at March 31, 2026, down from $19.5M at year-end 2025; excludes $10M April offering
- Phase 3 AD trial 85% enrolled; full enrollment expected summer 2026, top-line symptomatic data early 2027
- R&D expenses $16.7M vs $5.0M YoY, driven by Phase 3 trial costs; G&A flat at $1.3M
- Shares outstanding 28.5M at March 31, up from 27.2M at year-end 2025, reflecting ongoing dilution
Financial Impact
EPS miss of -$0.28 vs consensus; net loss increased $12.1M YoY; cash burn rate ~$5.9M/month
Risk Factors
- Cash runway insufficient to reach Phase 3 data readout without dilutive financing
- EPS miss and widening losses may pressure the stock given limited analyst coverage (1 analyst)
- Regulatory and clinical execution risk for buntanetap NDA submission in early 2027
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3295755 |
Track record
19 reports on ANVS
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 13, 20263d ago Press Release Neutral 5/10 Entry $0.9261 Now $0.7500 −19.02% settles Feb 11
- Nov 5, 202611d ago 8-K Bearish 7/10 Entry $0.8449 Now $0.7500 +11.23% settles Feb 4
- Nov 5, 202611d ago 424B5 Bearish 7/10 Entry $0.8449 Now $0.7500 +11.23% settles Feb 4
- Nov 5, 202611d ago Press Release Bearish 7/10 Entry $0.6689 Now $0.7500 −12.12% settles Feb 3
- Nov 4, 202612d ago 424B5 Bearish 6/10 Entry $0.6689 Now $0.7500 −12.12% settles Feb 3
- Nov 4, 202612d ago Press Release Bearish 7/10 Entry $0.6689 Now $0.7500 −12.12% settles Feb 3
- Nov 4, 202612d ago 8-K Bearish 7/10 Entry $0.6689 Now $0.7500 −12.12% settles Feb 3
- Oct 30, 202617d ago 8-K Bearish 7/10 Entry $1.08 Now $0.7500 +30.56% settles Jan 29
- Oct 19, 202628d ago 8-K Neutral 1/10 Entry $0.9783 Now $0.7500 −23.34% settles Jan 15
- Oct 15, 20264w ago SC 13G/A Neutral 3/10 Entry $1.05 Now $0.7500 −28.57% settles Jan 12
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers